European Union Requires NAION Warnings for Semaglutide In June 2025, the European Medicines Agency (EMA) required semaglutide products Ozempic, Wegovy and Rybelsus to include a warning that the medications may cause a very rare increased risk of NAION
Journal of the American College of Cardiology, 84(1), 27-40
You Don't Have To Choose Between Your Body Or Your Hair, Either For months, I thought I faced an impossible choice: Choice 1 Stay on Ozempic and keep losing my hair, confidence and femininity
Even with a preservative, improper handling can introduce microorganisms, compromising experimental results and the stability of sensitive materials
One of the biggest concerns for people who shed significant weight on these drugs is the disproportionate amount of lean muscle mass they can lose
Semaglutide GLP-1 injections are typically recommended for individuals with a BMI of 30 or higher, indicating obesity, or those with a BMI of 27 or higher and associated weight-related health conditions